{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-115211","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.996564+00:00","generated_at":"2026-05-15T09:39:04.091185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mereo BioPharma FY2025 net loss $41.9M; setrusumab Phase 3 studies miss primary endpoints, show BMD gains","bullets":["Cash $41.0M as of Dec 31, 2025; expected runway into mid-2027 (from $69.8M end 2024).","Setrusumab Phase 3 Orbit & Cosmic missed primary endpoint (annualized clinical fracture rate) but achieved high statistical significance on BMD improvement.","Setrusumab showed vertebral fracture reductions and statistically significant PRO improvements in pain/daily activity in pediatric patients.","Alvelestat site feasibility for Phase 3 in AATD-LD complete; partnering discussions ongoing; Phase 2b in bronchiectasis designed.","Vantictumab outlicensed to āshibio; Phase 2 in osteopetrosis planned H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-115211","json":"https://secwatch.observer/filing/0001193125-26-115211.json","markdown":"https://secwatch.observer/filing/0001193125-26-115211.md","text":"https://secwatch.observer/filing/0001193125-26-115211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/0001193125-26-115211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/mreo-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:39:04.091185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f4ec886a598e70581c8e75df735b0693940920c","claim":"Mereo BioPharma Group plc reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/0001193125-26-115211-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}